Upadacitinib

CHEBI:CHEBI_747557

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

rxcui
2681019
active_ingredient_strength
.5 kg/.5kg
package_marketing_start_date
26-MAR-23
pharm_class_epc
Janus Kinase Inhibitor [EPC]
pharm_class
Janus Kinase Inhibitors [MoA]
pharm_class_moa
Janus Kinase Inhibitors [MoA]
manufacturer_name
AbbVie Inc.
active_ingredient_name
UPADACITINIB HEMIHYDRATE
unii
4RA0KN46E0
spl_set_id
2966aec7-2ef0-923c-d8ff-fe1a957bf095
nui
N0000190857
package_description
30 TABLET, EXTENDED RELEASE in 1 BOTTLE (0074-2306-30)
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class
generic_name
UPADACITINIB HEMIHYDRATE
product_type
BULK INGREDIENT
marketing_category
BULK INGREDIENT
listing_expiration_date
20241231
route
ORAL
dosage_form
SOLUTION
marketing_start_date
20230326
labeler_name
HOSTER LABS PRIVATE LIMITED
product_ndc
68513-2310
spl_id
ec0dd0fc-f329-44fb-9f1a-8bcb8482c32c
package_ndc
68513-2310-9
brand_name
Rinvoq
brand_name_base
Rinvoq
application_number
NDA211675